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BACKGROUND
Asthma is a heterogeneous disease, usually characterised by (a)
chronic airway inflammation with variable symptoms of wheeze,
shortness of breath, chest tightness and/or cough, and (b) variable
expiratory airflow limitation.1 Despite increasing evidence-based
guidelines for asthma gaps between recommended care and
current practice remain.2, 3 Frequent and increasing use of short
acting beta2-agonists (SABA) or reliever therapy is a marker for
poor asthma control and increased risk of asthma attacks,4 with
control defined as the degree to which the manifestations of
asthma are minimised by treatment.5 Asthma control can be
assessed by reviewing both current symptoms and risk factors
(modifiable or non-modifiable) of future asthma attacks.1, 6 Poor
asthma control and risk of asthma attacks can be determined in
part by SABA use,7–12 with high or increasing SABA use a
potentially modifiable risk factor for asthma attacks9, 11, 13, 14 and
asthma related death.7, 8, 15 Poor asthma control is commonly due
to suboptimal asthma management and can result not only in loss
of school and workdays at a high cost for countries16–18 but also in
unnecessary morbidity and even mortality.3, 19 The National
Review of Asthma Deaths identified that 39% of people who died
from asthma had been prescribed more than 12 SABA inhalers in
the year before death and 4% had been prescribed more than 50
SABA inhalers in the year before death.15 Recent figures show that
asthma deaths are at the highest level for a decade with a 17%
increase in the number of asthma related deaths from 2014 to
2015 in England and Wales.20
Computer decision support systems (CDSSs) are increasingly
being used to improve the prevention and management of
chronic conditions such as asthma.21, 22 CDSSs include electronic
alerts and reminders that use patient-specific information and
clinical data to help healthcare providers make decisions that
enhance patient care.21, 23 Whilst CDSSs have the potential to
improve prescribing efficiency for healthcare professionals24–27
overall effectiveness in clinical practice is unclear.28 Recommenda-
tions have called for the electronic surveillance of prescription
refill frequency in primary care to alert clinicians to patients being
prescribed excessive quantities of SABA15; however it is unclear to
what extent alerts have been used in the management of SABA
prescribing and what impact, if any, they have on patient
outcomes.
AIMS
We aim to identify and critically appraise studies that have used
electronic alerts to identify people with asthma being prescribed
excessive SABA in primary care.
Specific objectives are as follows:
1. Evaluate the effectiveness of electronic alerts within CDSSs to
identify people with asthma being prescribed excessive SABA
in primary care.
2. Determine the features of electronic surveillance systems that
have the potential to improve process outcomes for
healthcare providers and clinical outcomes for people with
asthma.
DISCUSSION AND CONCLUSION
CDSS interventions can potentially increase adherence to
evidence-based medical knowledge, reduce unnecessary variation
in clinical practice and improve clinical decision-making pro-
cesses29, 30 particularly in the prevention and management of
chronic conditions.21 Studies addressing the use of CDSSs in the
care of people with asthma have shown varying results. One study
reported that CDSSs had little effect on clinical and process
outcomes for asthma due to low clinician use22 whilst another
reported that CDSSs can improve chronic disease processes and
outcomes particularly in the support of asthma self-
management.21 Alerts represent an important category of
decision support to clinicians, often having a substantial effect
on prescribing behaviour.31 However few studies have assessed
the impact of computerised alerts on clinical or health service
management outcomes.31 Current recommendations include the
use of alerts within general practice computer software to identify
patients with asthma being prescribed excessive quantities of
SABA.15, 32 A thorough synthesis of the evidence is required to: (i)
determine the extent to which electronic alerts to identify people
with asthma being prescribed excessive SABA in primary care can
improve asthma management and patient outcomes; (ii) clarify
the design and implementation of CDSSs alerts to improve asthma
prescribing decisions for clinicians.
METHODS
Study eligibility criteria
Types of studies. We will include all types of randomised controlled trials
in which patients have been treated by clinical teams informed by an
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electronic SABA prescribing alert compared with usual care. As a surrogate
measure of prescribing, studies using dispensing data will be included. We
will exclude non-randomised trial designs (quasi-experimental, observa-
tional studies); study protocols; paper-based tools (e.g., flow charts and
non-electronic clinical pathway tools); CDSS alerts used for conditions that
are not asthma, e.g., COPD or other respiratory conditions; CDSS alerts
used in secondary or tertiary care.
Types of participants. We will include studies involving healthcare
professionals and non-clinical staff in primary care who provide care to
adults and/or children with a physician coded asthma diagnosis.
Types of intervention. We will include studies which used CDSS based
alerts initiated by the excessive prescribing of SABA for people with
asthma. Definitions of excessive prescribing will be analysed on an
individual study basis.
Types of outcome measures. The primary outcome will be study-defined
SABA over-prescription. Secondary outcomes will be SABA prescribing,
inhaled corticosteroid (ICS) prescribing alone or with a long-acting beta2-
agonist, the ratio of ICS-SABA prescribed, asthma reviews, study-defined
asthma exacerbations, study-defined asthma exacerbations requiring oral
steroids, unscheduled consultations for asthma (including general practice
visits, emergency department visits and hospitalisations for asthma) and
study-defined asthma control assessment.
Search strategy
We will search the international electronic databases: MEDLINE (Ovid),
EMBASE (Ovid), CINAHL (Cumulative Index to Nursing and Allied Health
Literature), SCOPUS (Elsevier) and Cochrane Library (Wiley). Additional
studies will be retrieved by searching the references of eligible papers.
Unpublished and in-progress studies will be identified by searching online
trial registries; ISRCTN registry and ClinicalTrials.gov. All databases will be
searched from 1990 to July 2016. No language restrictions will be imposed;
translations will be sought where possible. Supplementary Appendix 1
presents details of our search strategy, which was developed for MEDLINE
and will be adapted in searching other databases.
Screening of retrieved literature. The titles and abstracts of all papers
retrieved from the databases will be checked independently by two
reviewers against the criteria of the study. The full texts of papers that are
potentially eligible will be retrieved and further assessed for inclusion
independently by two reviewers. Discrepancies in the screening processes
between the two reviewers will be resolved by consensus, and
disagreements will be arbitrated by a third reviewer.
Data extraction
A customised data collection form will be used by two reviewers,
independently, to extract relevant study data from full-text papers selected
for inclusion. The form will be piloted and refined before being applied to
full-text reports. Included papers will be discussed by the two reviewers
after data extraction, and disagreements will be arbitrated by a third
reviewer. Where necessary, clarification and additional data will be sought
from study authors. Key findings from each included study will be
summarised and tabulated.
Quality assessment
We will assess the risk of bias in each trial using the seven-criteria approach
described in section eight of the Cochrane Handbook for Systematic
Reviews of Interventions.33 Overall, each study will be rated as follows: A:
low risk of bias—no bias found; B: moderate risk of bias—one criterion for
risk of bias; C: high risk of bias—more than one criterion for risk of bias.
Data synthesis
Narrative synthesis of heterogeneous process outcomes (prescribing and
asthma reviews) and clinical outcomes (exacerbations, unscheduled
consultations and asthma control) will be conducted. Data will be
presented in tabular form. Where possible, meta-analysis will be performed
on process and clinical variables of interest, specifically: study-defined
SABA over-prescription, study-defined asthma exacerbations and study-
defined asthma control.
Heterogeneity will be assessed using the I-squared statistic. Where
possible, subgroup analyses will be performed on age categories as
defined by BTS/SIGN Guidelines; less than 5 years, aged 5–12 years and
greater than 12 years of age.4
Registration and reporting
This study is registered with PROSPERO, the University of York Centre for
Reviews and Dissemination International prospective register of systematic
reviews (CRD42016035633).
We will report according to the PRISMA guidelines for reporting
systematic reviews.34
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